Comparative Pharmacology
Head-to-head clinical analysis: ELIXOPHYLLIN versus TRUPHYLLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELIXOPHYLLIN versus TRUPHYLLINE.
ELIXOPHYLLIN vs TRUPHYLLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits phosphodiesterase, increasing intracellular cAMP, leading to bronchodilation and anti-inflammatory effects.
Truphylline is a xanthine derivative that inhibits phosphodiesterase (PDE) and blocks adenosine receptors, leading to bronchodilation, increased respiratory drive, and anti-inflammatory effects.
Theophylline (Elixophyllin) immediate-release: Initial dose 300 mg/day PO divided every 6-8 hours; titrate based on serum theophylline concentration (target 5-15 mcg/mL). Typical adult dose 400-600 mg/day PO divided every 6-8 hours. Sustained-release: 400-600 mg/day PO every 12 hours.
Aminophylline 5-6 mg/kg IV loading dose over 20-30 minutes, then 0.5-0.7 mg/kg/h continuous IV infusion; theophylline 300-600 mg PO daily divided q6-12h, titrated to serum theophylline level of 5-15 mcg/mL.
None Documented
None Documented
Terminal elimination half-life in adults is approximately 7-9 hours (range 3-12 hours) for non-smokers, and 4-5 hours for smokers. In children (1-9 years), half-life averages 3-4 hours; in neonates, it is prolonged (20-30 hours). Clinical context: Half-life may be increased in hepatic impairment, congestive heart failure, and with concurrent administration of drugs that inhibit CYP1A2 and CYP3A4 (e.g., cimetidine, erythromycin, ciprofloxacin). Decreased half-life occurs with enzyme inducers (e.g., phenytoin, carbamazepine, rifampin, smoking).
Terminal half-life: adults 6-8 hours, children 3-5 hours, neonates 24+ hours. Prolonged in hepatic or cardiac impairment.
Theophylline is primarily eliminated by hepatic metabolism (approximately 90%), with less than 10% excreted unchanged in urine. Renal excretion of unchanged drug accounts for about 10% in adults, but in neonates and infants, it may be higher (up to 50%). Fecal excretion is negligible (<1%).
Renal excretion of unchanged drug (80-90%) and metabolites; biliary/fecal elimination <10%.
Category C
Category C
Xanthine Bronchodilator
Xanthine Bronchodilator